TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06697210

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: • Dental Floss (Vitis®, Dentaid, Barcelona, Spain).
Description: Dental Floss: A piece of dental floss approximately 40-50 cm in length was taken and placed between the index and middle fingers of each hand, leaving about 2-3 cm free in the middle. The floss was then inserted, embracing the mesial and distal surfaces, and moved up and down three times on each side

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: • Superfloss (Oral B®, Procter & Gamble, USA)
Description: Superfloss: The stiffened end was used to introduce the thread and the spongy-floss into the interproximal area on both the mesial and distal parts, and a gentle back-and-forth motion was applied to remove bacterial plaque. The spongy-floss was then pulled through to the regular floss section and gently slid under the gumline, followed by an up-and-down motion. These movements were repeated three times on each side.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: • Oral irrigator (Waterpick®, Water Pik, Inc., CO., USA)
Description: Oral Irrigator: The finest tip was selected and placed in the mesiobuccal, distobuccal, mesiolingual, and distolingual interproximal spaces. The irrigator was activated at medium power (2/3), and the process was repeated three times on each side for five seconds.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: • Interproximal brushes (Interprox®, Vitis, Dentaid, Spain)
Description: Interproximal Brush Group: According to the interproximal space, the appropriate size was selected for each case. The brush was then placed horizontally in the interproximal space mesially and distally, and a back-and-forth movement was performed three times on each side.
Study: NCT03709784

Intervention type: DRUG
Intervention: Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care
Description: This is an observational study of adult patients with SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.

Intervention type: OTHER
Intervention: One time survey
Description: One time survey
Study: NCT00654940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin (Lyrica)
Description: Oral, 75mg or 150mg capsules, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, matched capsules, BID
Study: NCT02711072

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 100 µ of intrathecal Morphine+ infiltration catheter with saline 5 ml/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 100 µ of intrathecal Morphine+ infiltration catheter with saline 5 ml/h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: infiltration group
Description: spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 1ml of saline + infiltration catheter with 5 ml/h of Bupivacaïne 0,125%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: infiltration group
Description: spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 1ml of saline + infiltration catheter with 5 ml/h of Bupivacaïne 0,125%.
Study: NCT02328014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-319
Description: Oral
Study: NCT02606669

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal Replacement
Description: Using a Meal Replacement product, supplemented by protein powder and multivitamin
Study: NCT01492855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopy
Description: Arthroscopy is offered for the patients who do not benefit from conservative treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-invasive treatment
Description: All patients will receive information and supervised exercises by a physiotherapist.
Study: NCT00528190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Itraconazole
Description: Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks
Study: NCT01870817

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Home jejunostomy feeding
Study: NCT03312985

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACAF surgery
Description: The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ACCF surgery
Description: Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
Study: NCT03511989

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bone borne distractor
Description: Bone borne distraction device

Intervention type: DEVICE
Group type: OTHER
Intervention: Tooth borne distractor
Description: Tooth borne distraction device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Segmental LF1 Osteotomy group 1

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Segmental LF1 Osteotomy group 1

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Segmental LF1 Osteotomy group 2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Segmental LF1 Osteotomy group 3
Study: NCT04568707

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample for serum (serology, biomarkers) and DNA
Study: NCT03169374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Technology
Description: Patients in this arm will participate in virtual reality sessions planned for 5 minutes at a time, during which they are shown relaxing virtual environments.
Study: NCT04063462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: pyrotinib, single agent, 400mg p.o once daily until disease progressed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: pyrotinib, single agent, 400mg p.o once daily until disease progressed
Study: NCT02752152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted counseling
Description: The counselor opens the computer-assisted information/educational interactive counseling program on the tablet computer and invites the participant to use the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted counseling
Description: The counselor opens the computer-assisted information/educational interactive counseling program on the tablet computer and invites the participant to use the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer-assisted counseling
Description: The counselor opens the computer-assisted information/educational interactive counseling program on the tablet computer and invites the participant to use the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-assisted counseling
Description: The counselor opens the computer-assisted information/educational interactive counseling program on the tablet computer and invites the participant to use the program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-demand counseling
Description: The counselor only invites the participants to ask questions about HIV and other STIs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: On-demand counseling
Description: The counselor only invites the participants to ask questions about HIV and other STIs.
Study: NCT04356378

Intervention type: OTHER
Intervention: Data record
Description: Data record
Study: NCT02752152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-demand counseling
Description: The counselor only invites the participants to ask questions about HIV and other STIs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On-demand counseling
Description: The counselor only invites the participants to ask questions about HIV and other STIs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard counseling
Description: The counselor gives face-to-face general information/education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard counseling
Description: The counselor gives face-to-face general information/education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard counseling
Description: The counselor gives face-to-face general information/education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard counseling
Description: The counselor gives face-to-face general information/education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appointment + reminder
Description: Has an appointment and receive reminders for further testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appointment + reminder
Description: Has an appointment and receive reminders for further testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appointment + reminder
Description: Has an appointment and receive reminders for further testing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Appointment + reminder
Description: Has an appointment and receive reminders for further testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Only receive reminders for further testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Only receive reminders for further testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Description: Only receive reminders for further testing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reminder
Description: Only receive reminders for further testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No appointment and no reminder
Description: No appointment and no reminders for further testing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No appointment and no reminder
Description: No appointment and no reminders for further testing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No appointment and no reminder
Description: No appointment and no reminders for further testing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: No appointment and no reminder
Description: No appointment and no reminders for further testing
Study: NCT04662710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 administered by IV infusion on Day 1 of Weeks 1 and 4 of each Q6W cycle as part of CAPOX chemotherapy, or 85 mg/m\^2 administered by IV infusion on Day 1 and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 administered PO twice daily (BID) on Days 1-14, 22-35 of each Q6W cycle as part of CAPOX chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m\^2 administered PO twice daily (BID) on Days 1-14, 22-35 of each Q6W cycle as part of CAPOX chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (or Levoleucovorin)
Description: Administered by IV infusion at 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) on Day 1, and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin (or Levoleucovorin)
Description: Administered by IV infusion at 400 mg/m\^2 (leucovorin) or 200 mg/m\^2 (levoleucovorin) on Day 1, and Week 1, 3 and 5 of each Q6W cycle as part of mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m\^2 bolus IV infusion followed by 2400 mg/m\^2 continuous IV infusion administered on Day 1, and Week 1, 3, 5, of each Q2W cycle as part of mFOLFOX6 chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400 mg/m\^2 bolus IV infusion followed by 2400 mg/m\^2 continuous IV infusion administered on Day 1, and Week 1, 3, 5, of each Q2W cycle as part of mFOLFOX6 chemotherapy.
Study: NCT04537390

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample collection
Description: Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development
Study: NCT02858193

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCMC-lys powder 1.35 g
Description: Powder for oral solution in sachets each containing 1.35 g of S-carboxymethyl-L-cysteine L-lysine monohydrate salt (SCMC-lys).~One sachet of the powder of the test formulation: (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) was dissolved in 100 mL of hot (not boiling) still mineral water. Additional 100 mL of still mineral water at room temperature were added and mixed. The solution was swallowed and the glass was rinsed with 40 mL of still mineral water that was also drunk by the subjects. The final administered volume was 240 mL. All subjects were in fasting conditions from the evening before (at least 10 h, overnight).The final administered volume was 240 mL for both the test and reference treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCMC-lys powder 1.35 g
Description: Powder for oral solution in sachets each containing 1.35 g of S-carboxymethyl-L-cysteine L-lysine monohydrate salt (SCMC-lys).~One sachet of the powder of the test formulation: (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) was dissolved in 100 mL of hot (not boiling) still mineral water. Additional 100 mL of still mineral water at room temperature were added and mixed. The solution was swallowed and the glass was rinsed with 40 mL of still mineral water that was also drunk by the subjects. The final administered volume was 240 mL. All subjects were in fasting conditions from the evening before (at least 10 h, overnight).The final administered volume was 240 mL for both the test and reference treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluifort® syrup
Description: Fluifort® 90 mg/mL syrup (15 mL corresponding to 1.35 g SCMC-lys)~Fifteen (15) mL of syrup (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) poured in a glass were drunk by the subjects. Afterward, the glass was rinsed twice with a volume of 100 mL and 125 mL of still mineral water and the rinses were drunk immediately by the subjects. The final administered volume was 240 mL for both the test and reference treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluifort® syrup
Description: Fluifort® 90 mg/mL syrup (15 mL corresponding to 1.35 g SCMC-lys)~Fifteen (15) mL of syrup (1.35 g of SCMC-lys corresponding to 750 mg of carbocysteine-free base) poured in a glass were drunk by the subjects. Afterward, the glass was rinsed twice with a volume of 100 mL and 125 mL of still mineral water and the rinses were drunk immediately by the subjects. The final administered volume was 240 mL for both the test and reference treatments.
Study: NCT02836977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur-uracil
Description: Eligible patients will receive tegafur-uracil orally at a dose of 400mg/day (100mg/Cap., 2 capsules each time, twice a day) and folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day) for one year.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tegafur-uracil
Description: Eligible patients will receive tegafur-uracil orally at a dose of 400mg/day (100mg/Cap., 2 capsules each time, twice a day) and folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day) for one year.
Study: NCT01642186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole plus leuprolide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of everolimus, letrozole and leuprolide
Study: NCT04316455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrative Yoga Therapy
Description: Participants having an hour in-person weekly session with qualified yoga therapist for 6-weeks. At each session, the personalised yoga practices including straightening and relaxing posture of yoga, yoga breathing, Combinations of sound and imagery yoga practices were given and asked to continue practice at home during the week.
Study: NCT02231580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN82451B
Description: BN82451B capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT04297774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality treatment
Description: 18 virtual reality training through Pablo system (30 minutes a time, 2-3 times a week). Postural transition included sit-to-stand, sit down, reaching to different directions, stepping to different directions with weight transfer, and bending the trunk forward and side to side. The controller was attached to lower extremity or trunk to control the game, such as elevator, hot air balloon, shooting cans, etc.
Study: NCT04428970

Intervention type: PROCEDURE
Intervention: Invasive ICP monitoring
Description: Insertion of a parenchymal pressure measuring probe
Study: NCT03459820

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-DCFPyL PET/CT
Description: 18F-DCFPyL Positron Emission Tomography/Computed Tomography Scan
Study: NCT01474512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80 mg Ixekizumab Dosing Regimens 1, 2, and 3
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT03917043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-2449
Description: Capsule, multiple dose cohorts, oral administration every day (QD) of a 28-day cycle
Study: NCT01118962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949). At the beginning of SP0962, the dose may be maintained, or increased or decreased by 100 mg /day, as deemed clinically appropriate to optimize tolerability and seizure reduction. Dose increases should be no faster than 100 mg/ day per week up to a maximum of 800 mg/ day. Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses for up to a 56-week Treatment Phase. The Treatment Phase was followed by a 5-week End-of-Study Phase, during which subjects had to be tapered off Lacosamide at a recommended decrease rate of 200 mg/ day per week.
Study: NCT02749708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX5183
Description: IRX5183 will be administered orally daily on days 1-28 of each cycle for 2 cycles of induction. In the phase I part of the study, there will be 3 dose levels (dose level 1 \[DL1\] with 50 mg, DL2 with 75 mg, and DL3 with 100 mg), with 1 additional dose level to be only used if excessive toxicity noted at the DL1. There will be no intra-patient dose escalation. A phase II portion of the study was originally planned, but the study was terminated prior to phase II enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRX5183
Description: IRX5183 will be administered orally daily on days 1-28 of each cycle for 2 cycles of induction. In the phase I part of the study, there will be 3 dose levels (dose level 1 \[DL1\] with 50 mg, DL2 with 75 mg, and DL3 with 100 mg), with 1 additional dose level to be only used if excessive toxicity noted at the DL1. There will be no intra-patient dose escalation. A phase II portion of the study was originally planned, but the study was terminated prior to phase II enrollment.
Study: NCT04297774

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: 18 standard rehabilitation sessions (60 minutes a time, 2-3 times a week). The rehabilitative protocol focus on strengthening, endurance training, ambulation, and ADL training that included: (1) Hip flexor and knee extensor strengthening with resistance progressing used by weight bag or Thera-band. (2) Cycle ergometer riding with increase speed and resistance. (3) Gait pattern and speed correcting through treadmill and parallel bar. (4) Hand functional training and strategy teaching for feeding, dressing, and toileting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: 18 standard rehabilitation sessions (60 minutes a time, 2-3 times a week). The rehabilitative protocol focus on strengthening, endurance training, ambulation, and ADL training that included: (1) Hip flexor and knee extensor strengthening with resistance progressing used by weight bag or Thera-band. (2) Cycle ergometer riding with increase speed and resistance. (3) Gait pattern and speed correcting through treadmill and parallel bar. (4) Hand functional training and strategy teaching for feeding, dressing, and toileting.
Study: NCT01089556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks